Protara Therapeutics, Inc. Net Income (Loss) Available to Common Stockholders, Basic
Protara Therapeutics, Inc. (TARA) reported Net Income (Loss) Available to Common Stockholders, Basic of -$40.42 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-13.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2024-03-13
- Protara Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2023-12-31 was -$10.22M.
- Protara Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2023-09-30 was -$9.86M.
- Protara Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2023-06-30 was -$29.38M.
- Protara Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2023-03-31 was $9.04M, a 15.90% decline year-over-year.
- Protara Therapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2023 was -$40.42M.
- Protara Therapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2022 was -$65.95M, a 239.58% decline from fiscal 2021.
- Protara Therapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2021 was $47.25M, a 39.07% increase from fiscal 2020.
- Protara Therapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2020 was $33.98M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month as first filed |
|---|---|---|---|---|---|
| 2023-12-31 | -$10.22M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | -$20.08M derived: sum of 2 quarters · filed 2024-03-13 | -$49.47M derived: sum of 3 quarters · filed 2024-03-13 | -$40.42M 10-K · filed 2024-03-13 | |
| 2023-09-30 | -$9.86M 10-Q · filed 2023-11-03 | -$39.24M derived: sum of 2 quarters · filed 2023-11-03 | -$30.20M 10-Q · filed 2023-11-03 | -$69.17M derived: sum of 4 quarters · filed 2024-03-13 | |
| 2023-06-30 | -$29.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$20.34M 10-Q · filed 2023-08-03 | -$59.31M derived: sum of 3 quarters · filed 2024-03-13 | -$67.00M derived: sum of 4 quarters · filed 2024-03-13 | |
| 2023-03-31 | $9.04M 10-Q · filed 2023-05-04 | -$29.92M derived: sum of 2 quarters · filed 2024-03-13 | -$37.61M derived: sum of 3 quarters · filed 2024-03-13 | -$67.66M derived: sum of 4 quarters · filed 2024-03-13 | |
| 2022-12-31 | -$38.97M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | -$46.66M derived: sum of 2 quarters · filed 2024-03-13 | -$76.71M derived: sum of 3 quarters · filed 2024-03-13 | -$65.95M 10-K · filed 2024-03-13 | $65.95M 10-K · filed 2023-03-08 |
| 2022-09-30 | -$7.69M 10-Q · filed 2023-11-03 | -$37.74M derived: sum of 2 quarters · filed 2023-11-03 | -$26.98M 10-Q · filed 2023-11-03 | ||
| 2022-06-30 | -$30.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$19.29M 10-Q · filed 2023-08-03 | |||
| 2022-03-31 | $10.76M 10-Q · filed 2023-05-04 | ||||
| 2021-12-31 | $47.25M 10-K · filed 2023-03-08 | ||||
| 2020-12-31 | $33.98M 10-K · filed 2022-03-09 | ||||
| 2019-09-30 | -$1.54M 10-Q · filed 2019-10-31 | -$6.85M derived: sum of 2 quarters · filed 2019-10-31 | -$13.38M 10-Q · filed 2019-10-31 | -$18.64M derived: sum of 4 quarters · filed 2019-10-31 | |
| 2019-06-30 | -$5.32M 10-Q · filed 2019-08-07 | -$11.85M 10-Q · filed 2019-08-07 | -$17.11M derived: sum of 3 quarters · filed 2019-08-07 | -$21.61M derived: sum of 4 quarters · filed 2019-10-31 | |
| 2019-03-31 | -$6.53M 10-Q · filed 2019-05-08 | -$11.79M derived: sum of 2 quarters · filed 2019-05-08 | -$16.30M derived: sum of 3 quarters · filed 2019-10-31 | -$21.18M derived: sum of 4 quarters · filed 2019-10-31 | |
| 2018-12-31 | -$5.26M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13 | -$9.77M derived: sum of 2 quarters · filed 2019-10-31 | -$14.65M derived: sum of 3 quarters · filed 2019-10-31 | -$20.73M 10-K · filed 2019-03-13 | |
| 2018-09-30 | -$4.51M 10-Q · filed 2019-10-31 | -$9.39M derived: sum of 2 quarters · filed 2019-10-31 | -$15.47M 10-Q · filed 2019-10-31 | -$21.02M derived: sum of 4 quarters · filed 2019-10-31 | |
| 2018-06-30 | -$4.88M 10-Q · filed 2019-08-07 | -$10.96M 10-Q · filed 2019-08-07 | -$16.51M derived: sum of 3 quarters · filed 2019-08-07 | -$35.56M derived: sum of 4 quarters · filed 2019-08-07 | |
| 2018-03-31 | -$6.08M 10-Q · filed 2019-05-08 | -$11.63M derived: sum of 2 quarters · filed 2019-05-08 | -$30.69M derived: sum of 3 quarters · filed 2019-05-08 | -$36.29M derived: sum of 4 quarters · filed 2019-05-08 | |
| 2017-12-31 | -$5.55M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13 | -$24.61M derived: sum of 2 quarters · filed 2019-03-13 | -$30.21M derived: sum of 3 quarters · filed 2019-03-13 | -$36.71M 10-K · filed 2019-03-13 | |
| 2017-09-30 | -$19.05M 10-Q · filed 2018-11-07 | -$24.66M derived: sum of 2 quarters · filed 2018-11-07 | -$31.16M 10-Q · filed 2018-11-07 | -$38.12M derived: sum of 4 quarters · filed 2018-11-07 | |
| 2017-06-30 | -$5.61M 10-Q · filed 2018-08-07 | -$12.11M 10-Q · filed 2018-08-07 | -$19.07M derived: sum of 3 quarters · filed 2018-08-07 | -$26.18M derived: sum of 4 quarters · filed 2018-08-07 | |
| 2017-03-31 | -$6.50M 10-Q · filed 2018-05-09 | -$13.46M derived: sum of 2 quarters · filed 2018-05-09 | -$20.57M derived: sum of 3 quarters · filed 2018-05-09 | -$28.47M derived: sum of 4 quarters · filed 2018-05-09 | |
| 2016-12-31 | -$6.96M 10-K · filed 2017-03-16 | -$14.07M derived: sum of 2 quarters · filed 2017-11-07 | -$21.97M derived: sum of 3 quarters · filed 2017-11-07 | -$28.53M 10-K · filed 2019-03-13 | |
| 2016-09-30 | -$7.11M 10-Q · filed 2017-11-07 | -$15.01M derived: sum of 2 quarters · filed 2017-11-07 | -$21.56M 10-Q · filed 2017-11-07 | -$27.91M derived: sum of 4 quarters · filed 2017-11-07 | |
| 2016-06-30 | -$7.91M 10-Q · filed 2017-08-07 | -$14.46M 10-Q · filed 2017-08-07 | -$20.80M derived: sum of 3 quarters · filed 2017-08-07 | -$26.18M derived: sum of 4 quarters · filed 2017-08-07 | |
| 2016-03-31 | -$6.55M 10-Q · filed 2017-05-10 | -$12.89M derived: sum of 2 quarters · filed 2017-05-10 | -$18.28M derived: sum of 3 quarters · filed 2017-05-10 | -$23.35M derived: sum of 4 quarters · filed 2017-05-10 | |
| 2015-12-31 | -$6.34M 10-K · filed 2017-03-16 | -$11.72M derived: sum of 2 quarters · filed 2017-03-16 | -$16.80M derived: sum of 3 quarters · filed 2017-03-16 | -$21.38M 10-K · filed 2018-03-14 | |
| 2015-09-30 | -$5.38M 10-K · filed 2017-03-16 | -$10.46M derived: sum of 2 quarters · filed 2017-03-16 | -$15.04M 10-Q · filed 2016-11-07 | -$9.10M derived: sum of 4 quarters · filed 2017-03-16 | |
| 2015-06-30 | -$5.07M 10-K · filed 2017-03-16 | -$9.65M 10-Q · filed 2016-08-08 | -$3.71M derived: sum of 3 quarters · filed 2017-03-16 | -$11.17M derived: sum of 4 quarters · filed 2017-03-16 | |
| 2015-03-31 | -$4.58M 10-K · filed 2017-03-16 | $1.36M derived: sum of 2 quarters · filed 2017-03-16 | -$6.10M derived: sum of 3 quarters · filed 2017-03-16 | -$10.56M derived: sum of 4 quarters · filed 2017-03-16 | |
| 2014-12-31 | $5.94M 10-K · filed 2016-03-14 | -$1.52M derived: sum of 2 quarters · filed 2016-03-14 | -$5.98M derived: sum of 3 quarters · filed 2016-03-14 | -$9.70M 10-K · filed 2017-03-16 | |
| 2014-09-30 | -$7.46M 10-K · filed 2016-03-14 | -$11.92M derived: sum of 2 quarters · filed 2016-03-14 | -$16.26M 10-Q · filed 2015-11-12 | -$20.20M derived: sum of 4 quarters · filed 2016-03-14 | |
| 2014-06-30 | -$4.46M 10-K · filed 2016-03-14 | -$8.80M 10-Q · filed 2015-08-13 | -$12.74M derived: sum of 3 quarters · filed 2016-03-14 | -$16.38M derived: sum of 4 quarters · filed 2016-03-14 | |
| 2014-03-31 | -$4.34M 10-K · filed 2016-03-14 | -$8.28M derived: sum of 2 quarters · filed 2016-03-14 | -$11.92M derived: sum of 3 quarters · filed 2016-03-14 | -$15.00M derived: sum of 4 quarters · filed 2016-03-14 | |
| 2013-12-31 | -$3.94M 10-K · filed 2015-03-20 | -$7.58M derived: sum of 2 quarters · filed 2015-03-20 | -$10.65M derived: sum of 3 quarters · filed 2015-03-20 | -$14.03M 10-K · filed 2016-03-14 | |
| 2013-09-30 | -$3.64M 10-K · filed 2015-03-20 | -$6.72M derived: sum of 2 quarters · filed 2015-03-20 | -$10.09M 10-Q · filed 2014-11-25 | ||
| 2013-06-30 | -$3.07M 10-K · filed 2015-03-20 | -$6.45M derived: sum of 2 quarters · filed 2015-03-20 | |||
| 2013-03-31 | -$3.38M 10-K · filed 2015-03-20 | ||||
| 2012-12-31 | -$14.10M 10-K · filed 2015-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |